Drug development

#Cancer research #Cell profiling #Drug development #Financing #Next generation sequencing #One Biosciences

€15 million to advance clinical single cell profiling

One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences' total funding… Read More

#Business & Investment #News

#Denmark #Drug development #Funding #Obesity #Pila Pharma #Type 2 diabetes #Weight loss

Biotech raises capital for new oral obesity treatment

Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen and… Read More

#Business & Investment #News

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

#Career #Drug development #Drug discovery #England #From the top #Golden Triangle #Interview #Medicines Discovery Catapult #Nanomedicine / nanotechnology #Northern Ireland #Scotland #UK #University of Oxford

New podcast: UK Spotlight: Innovation and discovery

This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr… Read More

#News

#Drug development #Drug discovery #Meet the Researcher

What are the top books for life sciences researchers?

Both online and in the DDW quarterly magazine, DDW editors interview industry researchers to shine a spotlight on their work in a feature called Meet the Researcher. A question often included is: If you could make everyone read one book, article or academic paper, what would it be and why?… Read More

#Exclusive Content #Opinion

#DDW Turning Science into Business Symposium #Drug development #Drug discovery #Events

Secure your spot for the DDW Symposium

Register your interest for the DDW Turning Science into Business Symposium, which will take place at the Francis Crick Institute, one of Europe’s biggest biomedical labs, in London, UK in the afternoon on 4 November 2025. The half day event boasts a stellar line… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #ICON #Public health

ICON on the real-world integration of AI in drug R&D

DDW’s Megan Thomas speaks with ICON's IT Director, Marco Heldoorn, about leveraging artificial intelligence (AI) to enhance efficiency, decision-making, and patient outcomes across the drug development lifecycle, from early feasibility to post-marketing. MT: Could you provide an overview of your findings when it comes to drug development and AI? TO:… Read More

#Business & Investment #Exclusive Content

#Cytiva #Drug development #Nuclera #Proteins

Nuclera and Cytiva team up to accelerate protein production

Biotechnology company Nuclera and life sciences organisation Cytiva have announced a collaboration focused on accelerating the production, purification and characterisation of proteins required for drug research and development. The companies aim to enable this goal through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology. Read More

#News

#Drug development #Drug discovery #Obesity #RNA Therapeutics

New DDW Highlights podcast: 2 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli… Read More

#News

RNA
#Drug development #Drug discovery #Obesity #RNA Therapeutics

This week in drug discovery (26-30 May)

News round-up for 26-30 May by DDW Editor Reece Armstrong. News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson’s. Lilly and Rznomics agree $1.3 billion… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer #Drug development #Drug discovery

Insilico Medicine study validates ENPP1 as immune checkpoint for cancers  

Biotechnology company Insilico Medicine has unveiled a new study showcasing how the company’s advanced generative AI platform and integrated workflow helped to identify and validate ENPP1 as a critical immune checkpoint among multiple solid tumours, which helped to the development of a highly specific oral ENPP1 inhibitor, ISM5939. Read More

#News

#App note #Biopharma #Drug development

New guide: Unlocking the biopharma development pipeline

A new Introductory Guide is now available for download entitled ‘Unlocking the biopharma development pipeline‘. Discover a new generation of molecular sensing technology from Oxford Nanopore Technologies that is transforming the biopharma development pipeline. You’ll explore: How Oxford Nanopore sequencing overcomes challenges faced in the drug development process Advantages… Read More

#News

#App note #Biopharma #Drug development

Unlocking the biopharma development pipeline

A new Introductory Guide is now available for download entitled ‘Unlocking the biopharma development pipeline‘. Discover a new generation of molecular sensing technology from Oxford Nanopore Technologies that is transforming the biopharma development pipeline. You’ll explore: How Oxford Nanopore sequencing overcomes challenges faced in the drug development process Advantages… Read More

#Resources

#Biotechnology #Cardiometabolic diseases #Drug development #Drug discovery #ICON #Pharmaceuticals #Survey

More efficient next-gen obesity clinical trials needed, says survey

ICON has released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe, focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. Read More

#News

Double stranded DNA molecule with mutation in a gene
#Clinical trials #Cystic fibrosis #Drug delivery #Drug development #Europe #Kither Biotech

In Conversation With: Dimitrios Goundis, Kither Biotech

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO… Read More

#News

#Biotechnology #Drug development #MoonLake #Nanobodies

Meet the researcher: Kristian Reich

DDW’s Megan Thomas looks at a day in the life of Professor Kristian Reich, Co-Founder and CSO of MoonLake.  MT: Can you tell us what you do and what you’re working on at the moment? KR: As Co-Founder and Chief Scientific Officer of MoonLake, an advancing biotechnology company without the… Read More

#Exclusive Content